San Antonio Breast Cancer Symposium Updates (Dec 13-16 2008 San Antonio Texas)
Published: Fri Apr 29, 2011 Updated:Wed Sep 14, 2011We would like to thank Dr Sunil Verma for providing us with the late-breaking updates.
ATAC: 100 month median follow-up shows continued superior efficacy and no excess fracture risk for anastrozole compared with tamoxifen after treatment completion
Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well tolerated in women 65 or older
